Kazia Therapeutics (NASDAQ:KZIA) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
This table compares Kazia Therapeutics and Bio-Path’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
4.5% of Kazia Therapeutics shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Comparatively, 8.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a summary of current ratings and recommmendations for Kazia Therapeutics and Bio-Path, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Kazia Therapeutics and Bio-Path’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kazia Therapeutics||$90,000.00||181.49||-$4.68 million||($0.97)||-3.49|
Kazia Therapeutics has higher revenue and earnings than Bio-Path.
Volatility and Risk
Kazia Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of 3.5, indicating that its share price is 250% more volatile than the S&P 500.
Kazia Therapeutics beats Bio-Path on 5 of the 8 factors compared between the two stocks.
Kazia Therapeutics Company Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Bio-Path Company Profile
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.